News | January 11, 2026
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
Subscribe To Our Newsletter & Stay Updated
